Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 21,156	$ 14,032
Marketable securities	19,113	11,125
Prepaid and other current assets	989	815
Total current assets	41,258	25,972
Property and equipment, net	67	100
Other assets	694	1,081
Total assets	42,019	27,153
Liabilities
Accounts payable	1,105	1,490
Accrued liabilities	3,076	4,486
Total current liabilities	4,181	5,976
Other long-term liabilities	351	624
Total liabilities	4,532	6,600
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2020 and December 31, 2019, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 19,407,057 and 10,528,689 shares at September 30, 2020 and December 31, 2019, respectively	19	11
Additional paid-in capital	458,560	438,911
Treasury stock, at cost; 11,080 shares at September 30, 2020 and December 31, 2019	(708)	(708)
Accumulated deficit	(420,119)	(417,400)
Accumulated other comprehensive (loss) income	(12)	2
Total Caladrius Biosciences, Inc. stockholders' equity	37,740	20,816
Noncontrolling interests	(253)	(263)
Total stockholders' equity	37,487	20,553
Liabilities and Equity, Total	$ 42,019	$ 27,153